Report Store

The Report Store is a repository of research reports that are available for online purchase. Each provides an in-depth analysis of a single product or class of products in development within the pharmaceutical, biotechnology, device or diagnostics industries. The goal is to provide actionable insights that enable smart investment decisions around emerging product opportunities. Typically, the reports address:

The scientific and medical rationale for use in the target indication
The strength of available human efficacy and safety data, including the probability of late-phase trial success
Regulatory (eg, FDA) concerns and their likely impact on approval and labeling
Commercial opportunities, including an assessment of the competitive landscape and reimbursement issues.

Sort by

Lexicon's LX4211 - FDA canagliflozin decision is key bellweather

This report attempts to answer two basic questions: Will LX4211 gain regulatory approval and will it be able to gain market share vs competitors? Learn More

Lexicon's telotristat - A new approach to carcinoid syndrome

An analysis of efficacy, safety, regulatory approval, and market acceptance. Learn More

Obeticholic Acid - A novel treatment for chronic liver diseases

This report reviews obeticholic acid’s clinical, regulatory and commercial prospects across various indications. Learn More

Tesaro's Rolapitant: competition for Emend

This report reviews the underlying rationale for NK-1 therapy, the available phase II rolapitant data and the probability of phase III success, the history of relevant precedents and the probability of regulatory success, and importantly, rolapitant’s ability to compete against Emend in the marketplace. Learn More

ImmunoCellular Therapeutics' ICT-107 - Is 2013 the year of glioblastoma vaccines?

A review of IMUC's, Celldex's and Northwest Biotherapeutics' glioblastoma vaccines and the likelihood of clinical success. Learn More

Hyperion Therapeutics’ Ravicti (glycerol phenylbutyrate) - Opportunity in orphan and liver diseases

This report discusses the likelihood of Ravicti's approval in UCDs, strength of clinical evidence in HE, potential regulatory and marketing issues, and commercial prospects for Hyperion’s liver franchise.

Learn More

The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?

This report explores the probability of a favorable outcome for the CHAMPION-PHOENIX phase III trial, the likelihood of FDA approval, and the market opportunity for this novel P2Y12 receptor inhibitor. Learn More

Tranzyme's TZP-102 - Will it succeed where TZP-101 failed?

This report explores the novel ghrelin-based pharmacology and analyzes whether the failed TZP-101 experience applies to and predicts the outcome of the current TZP-102 program?

Learn More

PCSK9 Inhibitors - The hot new approach to lower cholesterol

An analysis of various PCSK9 inhibitors in development - the technology platforms, the early data, the regulatory path, the market opportunity. Learn More

Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide

A view of the evidence supporting palifosfamide’s development, the likelihood of clinical trial success, key regulatory hurdles as well as the commercial opportunity.
Learn More